Jove
Visualize
Contact Us

Related Concept Videos

Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of seasonality on conducting clinical studies in dermatology.

Clinics in dermatology·2008
Same author

Dermatologists in industry.

Journal of the American Academy of Dermatology·2007
Same author

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris.

Journal of the American Academy of Dermatology·2005
Same author

A novel foam vehicle for delivery of topical corticosteroids.

Journal of the American Academy of Dermatology·2005
Same author

The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris.

Journal of drugs in dermatology : JDD·2005
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 23, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Considerations before choosing (extemporaneously) compounded products.

Lincoln Krochmal1

  • 1Excaliard Pharmaceuticals, Carlsbad, California 92011, USA. lkrochmal@verizon.net

Dermatologic Therapy
|May 21, 2009
PubMed
Summary
This summary is machine-generated.

Extemporaneous compounding of topical medications remains relevant despite pharmaceutical options. Online sourcing increases risks for patients and physicians, necessitating updated guidelines for safe practice.

More Related Videos

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jun 23, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Area of Science:

  • Dermatology
  • Pharmaceutical Sciences
  • Medical Law

Background:

  • Numerous pre-packaged topical treatments exist for skin conditions.
  • Extemporaneous compounding, or custom medication formulation, persists at a low prescription rate (<1%).
  • Internet-based sourcing of compounded prescriptions has surged, introducing novel patient and physician risks.

Purpose of the Study:

  • To review and update technical, economic, and medico-legal issues of ad hoc compounding.
  • To provide practical recommendations for physicians and patients.
  • To mitigate risks associated with extemporaneously formulated products.

Main Methods:

  • Literature review of technical, economic, and medico-legal aspects.
  • Analysis of risks associated with online compounding services.
  • Development of evidence-based recommendations.

Main Results:

  • The practice of extemporaneous compounding presents multifaceted challenges.
  • Increased internet accessibility for compounding services elevates patient and physician risks.
  • Specific recommendations are proposed to address these identified risks.

Conclusions:

  • Physicians and patients must be aware of the risks linked to extemporaneous compounding.
  • Adherence to updated guidelines can minimize potential hazards.
  • Safe utilization of custom-formulated topical products requires informed decision-making.